U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07847398) titled 'Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.' on Sept. 17.
Brief Summary: The goal of this study is to investigate whether specific metabolic profiles can predict response to neoadjuvant chemo-immunotherapy in patients with stage II and III triple-negative breast cancer (TNBC).
The main objectives are to determine:
* whether targeted metabolic pathways, specifically tryptophan and diacetylspermine metabolism, are associated with histological response to neoadjuvant treatment;
* whether untargeted metabolomics combined with machine learning approach...